Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...
A new study shows that an interpretable AI model fusing 18F-PSMA-1007 PET/CT and multiparametric MRI can predict prostate ...
Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in ...
GRENOBLE, France and PRINCETON, N.J., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a global leader and innovator in prostate care, announced today the ...
GRENOBLE, France, March 20, 2025 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a global leader and innovator in urology and prostate care, announced today it is ...
InvestorsHub on MSN
Profound Medical and Telix Pharmaceuticals partner to advance prostate cancer imaging and treatment education
Profound Medical (NASDAQ:PROF) and Telix Pharmaceuticals (NASDAQ:TLX) have signed a co-education agreement aimed at increasing physician awareness of how advanced diagnostic imaging can support ...
High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...
A prospective study shows PSMA PET/CT-guided targeted biopsy detects clinically significant prostate cancer in 37 percent of ...
A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques.
PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results